부산대학교 도서관

Tralokinumab, a fully human monoclonal antibody, specifically binds to interleukin (IL)-13 of the type 2 cytokines involved in the pathogenesis and development of atopic dermatitis (AD) and inhibits IL-13 mediated signaling. It is approved for treating moderate-to-severe AD in several countries. The efficacy and safety of tralokinumab in moderate-to-severe adult AD patients were evaluated for Japanese subgroup of ECZTRA 1, a global clinical study of tralokinumab monotherapy, and ECZTRA 8, for which the study design was the same as that of a global clinical study (ECZTRA 3) of combination therapy with topical corticosteroids (TCS). Tralokinumab monotherapy and combination therapy with TCS in the Japanese cohort showed safety results consistent with both global clinical studies. Tralokinumab improved the signs and symptoms of AD in Japanese patients. However, efficacy results were not highly similar to those of the two global clinical studies, likely affected by the severity of illness at baseline, frequency of rescue therapy, and the amount of TCS used in ECZTRA 8. Long-term treatment up to 68 weeks was well tolerated in ECZTRA 1. These findings suggest that tralokinumab will be a valuable therapeutic option in adult Japanese patients with moderate-to-severe AD.